# MEDINEX LIMITED

Incorporated in the Republic of Singapore
Registration No. 200900689W

# Condensed Interim Financial Statements
# For the Six Months Ended 30 September 2026

*This announcement has been reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #04-02 Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.*

**Table of Contents**


A. Condensed Interim Consolidated Statement of Profit or Loss and Other Comprehensive Income ..... 1-2

B. Condensed Interim Statements of Financial Position of the Group and the Company ..... 3-4

C. Aggregate Amount of Group's Borrowings and Debt Securities ..... 4

D. Condensed Interim Statements of Changes in Equity ..... 5-7

E. Condensed Interim Consolidated Statements of Cash Flows ..... 8-9

F. Notes to the Condensed Interim Consolidated Financial Statements ..... 10-24

G. Other Information Required Pursuant to Appendix 7C of the Catalist Rules ..... 25-32

**A. Condensed Interim Consolidated Statement of Profit or Loss and Other Comprehensive Income**

| | Note | Group<br>6 months ended<br>30 September 2026 (Unaudited)<br>S$'000 | <br><br>30 September 2025 (Unaudited)<br>S$'000 | <br><br>Change<br>% |
|---|---|---|---|---|
| Revenue | 4 | 5,296 | 6,049 | (12.45) |
| **Other item of income** | | | | |
| Other income | | 91 | 956 | (90.48) |
| Reversal of loss allowance on receivables | | 41 | 83 | (50.60) |
| **Item of expense** | | | | |
| Changes in inventories | | (33) | (16) | 106.25 |
| Inventories and consumables | | (1,061) | (1,260) | (15.79) |
| Employee benefits expense | | (2,396) | (2,633) | (9.00) |
| Depreciation and amortisation expenses | | (170) | (256) | (33.59) |
| Loss allowance on trade receivables | | (34) | - | N.M. |
| Other expenses | | (612) | (711) | (13.92) |
| Finance costs | | (17) | (19) | (10.53) |
| Share of results of joint venture, net of tax | | 115 | 66 | 74.24 |
| Profit before income tax | 6 | 1,220 | 2,259 | (45.99) |
| Income tax expense | 7 | (107) | (163) | (34.36) |
| Profit for the financial period | | 1,113 | 2,096 | (46.90) |

**A. Condensed Interim Consolidated Statement of Profit or Loss and Other Comprehensive Income (cont'd)**

| | Note | Group<br>6 months ended<br>30 September 2026 (Unaudited)<br>S$'000 | <br><br>30 September 2025 (Unaudited)<br>S$'000 | <br><br>Change<br>% |
|---|---|---|---|---|
| **Other comprehensive income** | | | | |
| Foreign currency translation differences | | (2) | (2) | 0.00 |
| Other comprehensive income for the financial period, net of tax | | (2) | (2) | 0.00 |
| Total comprehensive income for the financial period | | 1,111 | 2,094 | (46.94) |
| **Profit attributable to:** | | | | |
| Owners of the company | | 1,113 | 2,096 | (46.90) |
| Non-controlling interests | | - | -* | N.M. |
| | | 1,113 | 2,096 | (46.90) |
| **Profit and total comprehensive income attributable to:** | | | | |
| Owners of the company | | 1,111 | 2,094 | (46.94) |
| Non-controlling interests | | - | -* | N.M. |
| | | 1,111 | 2,094 | (46.94) |
| Earnings per share (cents) | | | | |
| - Basic and diluted | 9 | 0.83 | 1.58 | (47.47) |

N.M. - not meaningful
*Value not more than S$1,000

**B. Condensed Interim Statements of Financial Position of the Group and the Company**

| | | Group | | Company | |
|---|---|---|---|---|---|
| | | 30 September 2026 (Unaudited) | 31 March 2026 (Audited) | 30 September 2026 (Unaudited) | 31 March 2026 (Audited) |
| | Note | S$'000 | S$'000 | S$'000 | S$'000 |
| **ASSETS** | | | | | |
| **Non-current assets** | | | | | |
| Plant and equipment | 13 | 136 | 154 | 13 | 10 |
| Right-of-use ("**ROU**") assets | | 608 | 749 | - | - |
| Intangible assets | 12 | 6,747 | 6,747 | - | - |
| Investment in subsidiaries | | - | - | 9,960 | 10,960 |
| Investment in joint venture | | 678 | 605 | 182 | 182 |
| Financial assets at fair value through profit or loss ("**FVTPL**") | 5, 11 | 2,606 | 2,722 | 2,605 | 2,721 |
| | | 10,775 | 10,977 | 12,760 | 13,873 |
| **Current assets** | | | | | |
| Inventories | | 303 | 335 | - | - |
| Trade and other receivables | | 1,841 | 2,455 | 1,346 | 1,267 |
| Contract assets | | 20 | 59 | - | - |
| Prepayments | | 71 | 118 | 46 | 96 |
| Fixed deposit | | - | 2,000 | - | 2,000 |
| Cash and bank balances | | 5,641 | 3,524 | 3,970 | 1,318 |
| | | 7,876 | 8,491 | 5,362 | 4,681 |
| **Total assets** | | 18,651 | 19,468 | 18,122 | 18,554 |
| **EQUITY AND LIABILITIES** | | | | | |
| **Equity** | | | | | |
| Share capital | 16 | 14,988 | 14,988 | 14,988 | 14,988 |
| Other reserves | | (1,950) | (1,950) | (2) | (2) |
| Foreign currency translation reserve | | (24) | (22) | - | - |
| Retained earnings | | 3,486 | 3,503 | 2,653 | 2,852 |
| **Total equity** | | 16,500 | 16,519 | 17,639 | 17,838 |

**B. Condensed Interim Statements of Financial Position of the Group and the Company (cont'd)**

| | Note | Group | | Company | |
|---|---|---|---|---|---|
| | | 30 September 2026 (Unaudited) | 31 March 2026 (Audited) | 30 September 2026 (Unaudited) | 31 March 2026 (Audited) |
| | | S$'000 | S$'000 | S$'000 | S$'000 |
| **Non-current liabilities** | | | | | |
| Lease liabilities | | 388 | 485 | - | - |
| Provisions | | 23 | 36 | - | - |
| | | 411 | 521 | - | - |
| **Current liabilities** | | | | | |
| Trade and other payables | | 974 | 1,219 | 427 | 674 |
| Contract liabilities | | 251 | 506 | - | - |
| Lease liabilities | | 213 | 249 | - | - |
| Bank borrowings | 14 | - | 262 | - | - |
| Current income tax payables | | 302 | 192 | 56 | 42 |
| | | 1,740 | 2,428 | 483 | 716 |
| **Total liabilities** | | 2,151 | 2,949 | 483 | 716 |
| **Total equity and liabilities** | | 18,651 | 19,468 | 18,122 | 18,554 |

**C. Aggregate amount of group's borrowing and debt securities**

| | Group | |
|---|---|---|
| | 30 September 2026 (Unaudited) | 31 March 2026 (Audited) |
| | S$'000 | S$'000 |
| **Amount repayable in one year or less, or on demand** | | |
| Unsecured | - | 262 |

**Details of any collaterals**

The Group's borrowings and debt securities are not secured by any collateral.

**D. Condensed Interim Statements of Changes in Equity**

| Group | Note | Share capital | Other reserves | Foreign currency translation reserve | Retained earnings | Total equity |
|---|---|---|---|---|---|---|
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) |
| | | S$'000 | S$'000 | S$'000 | S$'000 | S$'000 |
| Balance at 1 April 2026 | | 14,988 | (1,950) | (22) | 3,503 | 16,519 |
| **Other comprehensive income** | | | | | | |
| Foreign currency translation differences | | | | | | |
| - foreign operations | | - | - | (2) | - | (2) |
| Profit for the financial period | | - | - | - | 1,113 | 1,113 |
| **Total comprehensive income for the financial period** | | - | - | (2) | 1,113 | 1,111 |
| **Distribution to owners** | | | | | | |
| Dividends | 8 | - | - | - | (1,130) | (1,130) |
| **Total transactions with owners** | | - | - | - | (1,130) | (1,130) |
| Balance at 30 September 2026 | | 14,988 | (1,950) | (24) | 3,486 | 16,500 |

**D. Condensed Interim Statements of Changes in Equity (cont'd)**

| Group | Note | Share capital | Treasury shares | Other reserves | Foreign currency translation reserve | Retained earnings | Equity attributable to owners of the Parent | Non-controlling interests | Total equity |
|---|---|---|---|---|---|---|---|---|---|
| | | (Audited) | (Audited) | (Audited) | (Audited) | (Audited) | (Audited) | (Audited) | (Audited) |
| | | S$'000 | S$'000 | S$'000 | S$'000 | S$'000 | S$'000 | S$'000 | S$'000 |
| Balance at 1 April 2025 | | 14,571 | - | (1,348) | (19) | 3,516 | 16,720 | 7 | 16,727 |
| **Other comprehensive income** | | | | | | | | | |
| Foreign currency translation differences - foreign operations | | - | - | - | (2) | - | (2) | - | (2) |
| Profit for the financial period | | - | - | - | - | 2,096 | 2,096 | -* | 2,096 |
| **Total comprehensive income for the financial period** | | - | - | - | (2) | 2,096 | 2,094 | -* | 2,094 |
| Purchase of treasury shares | 16 | - | (185) | - | - | - | (185) | - | (185) |
| **Distribution to owners** | | | | | | | | | |
| Dividends | 8 | - | - | - | - | (1,108) | (1,108) | - | (1,108) |
| **Total transactions with owners** | | - | (185) | - | - | (1,108) | (1,108) | - | (1,108) |
| Balance at 30 September 2025 | | 14,571 | (185) | (1,348) | (21) | 4,504 | 17,521 | 7 | 17,528 |

*Value not more than S$1,000

**D. Condensed Interim Statements of Changes in Equity (cont'd)**

| Company | Note | Share capital (Unaudited) S$'000 | Treasury shares (Unaudited) S$'000 | Other reserves (Unaudited) S$'000 | Retained earnings (Unaudited) S$'000 | Total equity (Unaudited) S$'000 |
|---|---|---|---|---|---|---|
| Balance as 1 April 2026 | | 14,988 | - | (2) | 2,852 | 17,838 |
| **Profit for the financial period** | | - | - | - | 931 | 931 |
| **Total comprehensive income for the financial period** | | - | - | - | 931 | 931 |
| **Distribution to owners** | | | | | | |
| Dividends | 8 | - | - | - | (1,130) | (1,130) |
| **Total transactions with owners** | | - | - | - | (1,130) | (1,130) |
| Balance at 30 September 2026 | | 14,988 | - | (2) | 2,653 | 17,639 |

| Company | Note | Share capital (Unaudited) S$'000 | Treasury shares (Unaudited) S$'000 | Other reserves (Unaudited) S$'000 | Retained earnings (Unaudited) S$'000 | Total equity (Unaudited) S$'000 |
|---|---|---|---|---|---|---|
| Balance as 1 April 2025 | | 14,571 | - | 600 | 2,561 | 17,732 |
| **Profit for the financial period** | | - | - | - | 2,443 | 2,443 |
| **Total comprehensive income for the financial period** | | - | - | - | 2,443 | 2,443 |
| Purchase of treasury shares | 16 | - | (185) | - | - | (185) |
| **Distribution to owners** | | | | | | |
| **Dividends** | 8 | - | - | - | (1,108) | (1,108) |
| **Total transactions with owners** | | - | - | - | (1,108) | (1,108) |
| Balance at 30 September 2025 | | 14,571 | (185) | 600 | 3,896 | 18,882 |

**E. Condensed Interim Consolidated Statement of Cash Flows**

| | Note | Group<br>6 months ended<br>30 September 2026<br>(Unaudited)<br>S$'000 | <br><br>30 September 2025<br>(Unaudited)<br>S$'000 |
|---|---|---|---|
| **Operating activities** | | | |
| Profit before income tax | | 1,220 | 2,259 |
| Adjustments for: | | | |
| Amortisation of intangible assets | | - | 38 |
| Loss allowance on trade receivables | | 34 | - |
| Reversal of loss allowance on receivables | | (41) | (83) |
| Recovery of bad debts written off | | - | 8 |
| Bad debts written off | | - | 10 |
| Depreciation of plant and equipment | | 31 | 18 |
| Depreciation of ROU assets | | 139 | 200 |
| Reversal of provision for reinstatement no longer required | | (13) | - |
| Fair value loss/(gain) on financial assets at FVTPL | 11 | 113 | (884) |
| Gain on disposal of financial assets at FVTPL | | (33) | - |
| Dividend income from financial assets at FVTPL | | (14) | (21) |
| Interest income | | (1) | (1) |
| Interest expense | | 17 | 19 |
| Share of results of joint venture, net of tax | | (115) | (66) |
| Operating cash flows before working capital changes | | 1,337 | 1,497 |
| Working capital changes: | | | |
| Inventories | | 33 | 16 |
| Trade and other receivables | | 575 | 249 |
| Contract assets and contract liabilities | | (215) | (273) |
| Prepayments | | 46 | 25 |
| Trade and other payables | | (245) | (459) |
| Cash generated from operations | | 1,531 | 1,055 |
| Income tax refunded/(paid) | | 2 | (60) |
| Net cash from operating activities | | 1,533 | 995 |

**E. Condensed Interim Consolidated Statement of Cash Flows (cont'd)**

| | Note | Group 6 months ended 30 September 2026 (Unaudited) S$'000 | Group 6 months ended 30 September 2025 (Unaudited) S$'000 |
|---|---|---|---|
| Net cash from operating activities | | 1,533 | 995 |
| **Investing activities** | | | |
| Dividend income from joint venture | | 42 | - |
| Dividend income from financial assets at FVTPL | | 14 | 21 |
| Proceeds from disposal of financial asset at FVTPL | | 1,217 | 40 |
| Interest received | | 46 | 44 |
| Investment in financial asset at FVTPL | 11 | (1,181) | - |
| Purchase of plant and equipment | 13 | (13) | (6) |
| Net cash from investing activities | | 125 | 99 |
| **Financing activities** | | | |
| Repayment of principal portion of lease liabilities | | (130) | (212) |
| Repayments of interest portion of lease liabilities | | (16) | (13) |
| Repayment of bank borrowings | 14 | (262) | (257) |
| Interest paid for bank borrowings | | (1) | (6) |
| Purchase of treasury shares | 16 | - | (185) |
| Dividends paid to owners of company | 8 | (1,130) | (1,108) |
| Net cash used in financing activities | | (1,539) | (1,781) |
| Net change in cash and cash equivalents | | 119 | (686) |
| Cash and cash equivalents at beginning of financial period | | 5,524 | 5,555 |
| Effect of foreign exchange rate changes on cash and cash equivalents | | (2) | (2) |
| Cash and cash equivalents at end of financial period | | 5,641 | 4,867 |

## F. Notes to the Condensed Interim Consolidated Financial Statements

### 1. Corporate information

Medinex Limited (the " **Company**") is a public limited company incorporated and domiciled in Singapore. The Company was listed on the Catalist Board of the Singapore Exchange Securities Trading Limited ( the "**SGX-ST**") on 7 December 2018. These condensed interim consolidated financial statements as at and for the six months ended 30 September 2026 comprise the Company and its subsidiaries (collectively, the "**Group**"). The primary activity of the Company is that of an investment holding company.

The principal activities of the Group are:
(a) providing business support services;
(b) providing medical support services; and
(c) providing pharmaceutical services.

### 2. Basis of Preparation

The condensed interim financial statements for the six months ended 30 September 2026 have been prepared in accordance with SFRS(I) 1 -34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance of the Group since the last annual financial statements for the year ended 31 March 2026.

The accounting policies adopted are consistent with those of the previous financial year, which were prepared in accordance with Singapore Financial Reporting Standards (International) ("**SFRS(I)s**"), except for the adoption of new and amended standards as set out in Note 2.1.

The condensed interim financial statements are presented in Singapore dollars ("**S$**"), which is the Company's functional currency.

2.1. New and amended standards adopted by the Group

A number of amendments to Standards have become applicable for the current reporting period. The Group was not required to change its accounting policies or make any retrospective adjustments as a result of adopting these standards.

2.2. Use of judgements and estimates

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

## F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

### 2. Basis of Preparation (cont'd)

2.2. Use of judgements and estimates (cont'd)

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 March 2026.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

Information about critical judgements in applying accounting policies that have the most significant effect on the amounts recognised in the financial statements is included in the following notes:

- Note 11 – Classification of equity investments

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next interim period are included in the following notes:

- Note 12 – impairment test of intangible assets and goodwill: key assumptions underlying recoverable amounts

### 3. Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

### 4. Segment and revenue information

The Group is organised into the following main business segments:
- Segment 1: Medical support services
- Segment 2: Business support services
- Segment 3: Pharmaceutical services

**F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)**

**4. Segment and revenue information (cont'd)**

4.1. Reportable segments

| Business segment | Medical support services | Business support services | Pharmaceutical services | Unallocated expenses | Consolidated |
|---|---|---|---|---|---|
| **1 April 2026 to 30 September 2026** | **S$'000** | **S$'000** | **S$'000** | **S$'000** | **S$'000** |
| **Revenue** | | | | | |
| External revenue | 2,074 | 1,913 | 1,309 | - | 5,296 |
| **Profit from operations** | | | | | |
| Share of results from joint venture, net of tax | - | - | - | 115 | 115 |
| Interest income | - | - | 1 | 7 | 8 |
| Inventories and consumables used | - | - | 1,094 | - | 1,094 |
| Finance costs | 15 | 1 | 1 | -* | 17 |
| Amortisation and depreciation expense | 107 | 21 | 23 | 19 | 170 |
| Employee benefits expense | 194 | 488 | 245 | 1,469 | 2,396 |
| Income tax expense | 19 | 55 | - | 33 | 107 |
| Reportable segment profit/ (loss) before income tax | 1,736 | 1,281 | (87) | (1,710) | 1,220 |
| Net profit/(loss) for the financial period after tax | 1,717 | 1,226 | (87) | (1,743) | 1,113 |

*Value not more than S$1,000

**F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)**

**4. Segment and revenue information (cont'd)**

4.1. Reportable segments (cont'd)

| Business segment | Medical support services | Business support services | Pharmaceutical services | Medical services | Unallocated expenses | Consolidated |
|---|---|---|---|---|---|---|
| **1 April 2025 to 30 September 2025** | **S$'000** | **S$'000** | **S$'000** | **S$'000** | **S$'000** | **S$'000** |
| **Revenue** | | | | | | |
| External revenue | 2,219 | 2,127 | 1,463 | 240 | - | 6,049 |
| **Profit from operations** | | | | | | |
| Share of results from joint venture, net of tax | - | - | - | - | 66 | 66 |
| Interest income | 3 | - | 3 | 1 | (6) | 1 |
| Inventories and consumables used | 3 | - | 1,226 | 47 | - | 1,276 |
| Finance costs | 8 | 3 | 4 | 3 | 1 | 19 |
| Amortisation and depreciation expense | 100 | 52 | 26 | 24 | 54 | 256 |
| Employee benefits expense | 273 | 639 | 295 | 86 | 1,340 | 2,633 |
| Income tax expense | 73 | 54 | - | - | 36 | 163 |
| Reportable segment profit/ (loss) before income tax | 1,783 | 1,317 | (114) | 13 | (740) | 2,259 |
| Net profit/(loss) for the financial period after tax | 1,710 | 1,263 | (114) | 13 | (776) | 2,096 |

**F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)**

**4. Segment and revenue information (cont'd)**

4.1. Reportable segments (cont'd)

| Business segment | Medical support services | Business support services | Pharmaceutical services | Unallocated expenses | Consolidated |
|---|---|---|---|---|---|
| **1 April 2026 to 30 September 2026** | **S$'000** | **S$'000** | **S$'000** | **S$'000** | **S$'000** |
| Other information: | | | | | |
| Other material non-cash items | | | | | |
| -Impairment loss on receivables written back | (17) | (15) | - | - | (32) |
| -Loss allowance on trade receivables | 3 | 28 | 3 | - | 34 |
| -Reversal of loss allowance on receivables | (5) | (4) | - | - | (9) |
| -Reversal of provision for reinstatement no longer required | (13) | - | - | - | (13) |
| -Fair value loss on financial assets at FVTPL | - | - | - | 113 | 113 |
| -Gain on disposal of financial assets at FVTPL | - | - | - | (33) | (33) |
| -Dividend income from financial assets at FVTPL | - | - | - | (14) | (14) |
| Additions to non-current assets | | | | | |
| -plant and equipment | 3 | - | - | 11 | 14 |
| Segment assets | 188 | 1,429 | 1,247 | 15,787 | 18,651 |
| Segment liabilities | 432 | 497 | 709 | 514 | 2,152 |

*Value not more than S$1,000

**F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)**

**4. Segment and revenue information (cont'd)**

4.1. Reportable segments (cont'd)

| **Business segment** | **Medical support services** | **Business support services** | **Pharmaceutical services** | **Medical services** | **Unallocated expenses** | **Consolidated** |
|---|---|---|---|---|---|---|
| **1 April 2025 to 30 September 2025** | **S$'000** | **S$'000** | **S$'000** | **S$'000** | **S$'000** | **S$'000** |
| Other information: | | | | | | |
| Other material non-cash items | | | | | | |
| -Impairment loss on receivables written back | (24) | (59) | -* | -* | - | (83) |
| -Fair value gain on financial assets at FVTPL | - | - | - | - | 884 | 884 |
| - Dividend income from financial assets at FVTPL | - | - | - | - | 21 | 21 |
| Additions to non-current assets | | | | | | |
| -plant and equipment | - | - | - | - | 6 | 6 |
| Segment assets | 734 | 1,313 | 1,964 | 239 | 16,142 | 20,392 |
| Segment liabilities | 841 | 677 | 653 | 225 | 468 | 2,864 |

**F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)**

**4. Segment and revenue information (cont'd)**

4.2. Disaggregation of Revenue

| Business segment | Medical support services | | Business support services | | Pharmaceutical services | | Medical services | | Consolidated | |
|---|---|---|---|---|---|---|---|---|---|---|
| | 6 months ended | | | | | | | | | |
| | 30 September 2026 | 30 September 2025 | 30 September 2026 | 30 September 2025 | 30 September 2026 | 30 September 2025 | 30 September 2026 | 30 September 2025 | 30 September 2026 | 30 September 2025 |
| | S$'000 | S$'000 | S$'000 | S$'000 | S$'000 | S$'000 | S$'000 | S$'000 | S$'000 | S$'000 |
| Type of goods or services | | | | | | | | | | |
| Service fee | 2,074 | 2,219 | 1,913 | 2,127 | - | - | - | - | 3,987 | 4,346 |
| Sale of medical and pharmaceutical products | - | - | - | - | 1,309 | 1,463 | - | - | 1,309 | 1,463 |
| Provision of medical services | - | - | - | - | - | - | - | 240 | - | 240 |
| | 2,074 | 2,219 | 1,913 | 2,127 | 1,309 | 1,463 | - | 240 | 5,296 | 6,049 |
| Timing of transfer of goods and services | | | | | | | | | | |
| Point in time | 1,995 | 2,148 | 1,538 | 1,760 | 1,309 | 1,463 | - | 240 | 4,842 | 5,611 |
| Over time | 79 | 71 | 375 | 367 | - | - | - | - | 454 | 438 |
| | 2,074 | 2,219 | 1,913 | 2,127 | 1,309 | 1,463 | - | 240 | 5,296 | 6,049 |

**F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)**

**Geographical information**

The Group's operations are primarily carried out in Singapore. Accordingly, no geographical segment assets and revenue from external customers' information are presented.

**5. Financial assets and financial liabilities**

Set out below is an overview of the financial assets and financial liabilities of the Group as at 30 September 2026 and 31 March 2026:

| | Group | | Company | |
|---|---|---|---|---|
| | 30 September 2026 (Unaudited) | 31 March 2026 (Audited) | 30 September 2026 (Unaudited) | 31 March 2026 (Audited) |
| | S$'000 | S$'000 | S$'000 | S$'000 |
| **Financial assets** | | | | |
| Trade and other receivables | 1,841 | 2,455 | 1,346 | 1,267 |
| Cash and bank balances | 5,641 | 3,524 | 3,970 | 1,318 |
| Fixed deposit | - | 2,000 | - | 2,000 |
| At fair value through profit or loss | 2,606 | 2,722 | 2,605 | 2,721 |
| **Financial liabilities** | | | | |
| Trade and other payables | 820 | 991 | 396 | 643 |
| Lease liabilities | 601 | 734 | - | - |
| Bank borrowings | - | 262 | - | - |

## F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

### 6. Profit before taxation

6.1. Significant items

| | 6 months ended | |
|---|---|---|
| | 30 September 2026 (Unaudited) | 30 September 2025 (Unaudited) |
| | S$'000 | S$'000 |
| **Profit for the financial period is stated after charging the following:** | | |
| Fair value loss/(gain) on financial asset at FVTPL | 113 | (884) |
| Gain on disposal of financial assets at FVTPL | (33) | (8) |
| Dividend income from financial assets at FVTPL | (14) | (21) |
| Government grant | (14) | (23) |
| Interest income | (8) | (7) |
| Impairment loss on receivables written back | (32) | - |
| Reversal of loss allowance on receivables | (9) | (83) |
| Reversal of provision for reinstatement no longer required | (13) | - |
| Recovery of bad debts written off | - | (8) |
| Loss allowance on trade receivables | 34 | - |
| Amortisation of intangible assets | - | 38 |
| Depreciation of plant and equipment | 31 | 18 |
| Depreciation of ROU assets | 139 | 200 |
| Cost of services | 74 | 149 |
| Platform fees | 66 | 75 |
| Professional fees | 20 | 9 |

### 7. Taxation

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed interim consolidated statement of profit or loss are:

| | 6 months ended | |
|---|---|---|
| | 30 September 2026 (Unaudited) | 30 September 2025 (Unaudited) |
| | S$'000 | S$'000 |
| Current income tax | | |
| - current financial period | 107 | 163 |
| Total income tax expense recognised in profit or loss | 107 | 163 |

**F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)**

**8. Dividends**

| | Group | |
|---|---|---|
| | 6 months ended | |
| | 30 September 2026 (Unaudited) | 30 September 2025 (Unaudited) |
| | S$'000 | S$'000 |
| Final tax exempt dividend of S$0.0084 per ordinary share for the financial year ended 31 March 2026/ 31 March 2025 | 1,130 | 1,108 |

**9. Earnings Per Share**

The calculation for earnings per share ("**EPS**") is based on:

| | Group | |
|---|---|---|
| | 6 months ended | |
| | 30 September 2026 (Unaudited) | 30 September 2025 (Unaudited) |
| Profit attributable to owners of the company (S$'000) | 1,113 | 2,096 |
| Weighted-average number of ordinary shares used in issue during the financial period applicable to EPS | 134,543,843 | 132,353,243 |
| EPS (S$ cents) | | |
| – Basic and diluted | 0.83 | 1.58 |

The calculations of basic and diluted EPS are based on profit attributable to owners of the Company divided by the weighted average number of ordinary shares outstanding during the financial period.

The Group did not have any potential dilutive ordinary shares as at 30 September 2026 and 30 September 2025.

**10. Net Asset Value**

| | Group | | Company | |
|---|---|---|---|---|
| Net asset value ("NAV") | 30 September 2026 (Unaudited) | 31 March 2026 (Audited) | 30 September 2026 (Unaudited) | 31 March 2026 (Audited) |
| NAV (S$) | 16,500,000 | 16,519,000 | 17,639,000 | 17,838,000 |
| Number of ordinary shares in issue | 134,543,843 | 134,543,843 | 134,543,843 | 134,543,843 |
| NAV per ordinary share (S$ cents) | 12.26 | 12.28 | 13.11 | 13.26 |

## F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

### 11. Financial assets at fair value through profit and loss

| | Group | | Company | |
|---|---|---|---|---|
| | 30 September 2026 (Unaudited) S$'000 | 31 March 2026 (Audited) S$'000 | 30 September 2026 (Unaudited) S$'000 | 31 March 2026 (Audited) S$'000 |
| Quoted equity investments | 2,606 | 2,722 | 2,605 | 2,722 |
| | 2,606 | 2,722 | 2,605 | 2,722 |

Movement in financial assets at fair value through profit and loss as follows:

| | Group and Company | |
|---|---|---|
| | 30 September 2026 (Unaudited) S$'000 | 31 March 2026 (Audited) S$'000 |
| Balance at beginning of financial period/year | 2,722 | 2,483 |
| Fair value (loss)/gain | (113) | 586 |
| Addition | 1,181 | - |
| Disposal | (1,184) | (347) |
| Balance at end of financial period/year | 2,606 | 2,722 |

The instruments are all mandatorily measured at fair value through profit or loss.

11.1. Fair value measurement

The Group classifies financial assets measured at fair value using a fair value hierarchy which reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

a) Quoted prices (unadjusted) in active markets for identical assets or liabilities (Level 1);

b) Inputs other than quoted prices included within Level 1 which are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices) (Level 2); and

c) Inputs for the assets or liability which are not based on observable market data (unobservable inputs) (Level 3)

**F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)**

**11. Financial assets at fair value through profit and loss (cont'd)**

11.1. Fair value measurement (cont'd)

| | Fair value measurements using | | | |
|---|---|---|---|---|
| | Level 1 | Level 2 | Level 3 | Total |
| | S$'000 | S$'000 | S$'000 | S$'000 |
| **Group** | | | | |
| **30 September 2026** | | | | |
| **Financial assets** | | | | |
| Financial assets, at FVTPL | | | | |
| - Quoted equity securities | 2,606 | - | - | 2,606 |
| | 2,606 | - | - | 2,606 |
| **31 March 2026** | | | | |
| **Financial assets** | | | | |
| Financial assets, at FVTPL | | | | |
| - Quoted equity securities | 2,722 | - | - | 2,722 |
| | 2,722 | - | - | 2,722 |

**12. Intangible assets**

| | Customer listing | Goodwill | Software | Web development | Total |
|---|---|---|---|---|---|
| | S$'000 | S$'000 | S$'000 | S$'000 | S$'000 |
| **Group** | | | | | |
| **Cost** | | | | | |
| Balance at 1 April 2026 and 30 September 2026 | 657 | 8,604 | 27 | 6 | 9,294 |
| **Accumulated amortisation and impairment loss** | | | | | |
| Balance at 1 April 2026 and 30 September 2026 | 657 | 1,857 | 27 | 6 | 2,547 |
| **Net carrying amount** | | | | | |
| Balance at 30 September 2026 | - | 6,747 | - | - | 6,747 |
| Remaining useful life at end of financial period | - | Indefinite | - | - | |

**F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)**

**12. Intangible assets (cont'd)**

| | Customer listing S$'000 | Goodwill S$'000 | Software S$'000 | Web development S$'000 | Total S$'000 |
|---|---|---|---|---|---|
| **Group** | | | | | |
| **Cost** | | | | | |
| Balance at 1 April 2025 | 708 | 8,686 | 27 | 6 | 9,427 |
| Disposal | - | (82) | - | - | (82) |
| Written off | (51) | - | - | - | (51) |
| Balance at 31 March 2026 | 657 | 8,604 | 27 | 6 | 9,294 |
| **Accumulated amortisation and impairment loss** | | | | | |
| Balance at 1 April 2025 | 629 | 261 | 27 | 6 | 923 |
| Amortisation for the financial year | 75 | - | - | - | 75 |
| Impairment loss for the financial year | - | 1.596 | - | - | 1,596 |
| Written off | (47) | - | - | - | (47) |
| Balance at 31 March 2026 | 657 | 1,857 | 27 | 6 | 2,547 |
| **Net carrying amount** | | | | | |
| Balance at 31 March 2026 | - | 6,747 | - | - | 6,747 |
| Remaining useful life at end of financial year | - | Indefinite | - | - | |

Amortisation expenses were included under the line item "depreciation and amortisation expenses" of the condensed interim consolidated statement of profit or loss and other comprehensive income.

Goodwill arising from the business combination relates to the acquisition of subsidiaries that are expected to benefit from the business combination and the respective CGUs are Nex Healthcare Pte. Ltd. ("**Nex**"), Acctax Management Consultancy Private Limited ("**Acctax**"), MDX Professional Services Pte. Ltd. ("**MPS**"), Ark Leadership & Learning Pte. Ltd. ("**ARK**"), MDX Advisory Pte. Ltd. ("**MDX**") and Carlin Management Services Pte. Ltd. ("**CMS**") which are determined as one CGU respectively.

The carrying amount of goodwill had been allocated as follows:

| | 30 September 2026 (Unaudited) S$'000 | 31 March 2026 (Audited) S$'000 |
|---|---|---|
| **CGUs** | | |
| Nex | 794 | 794 |
| Acctax | 335 | 335 |
| MPS | 914 | 914 |
| ARK | 872 | 872 |
| MDX | 1,068 | 1,068 |
| CMS | 2,764 | 2,764 |
| | 6,747 | 6,747 |

## F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

### 13. Plant and equipment

During the six months ended 30 September 2026, the Group acquired assets amounting to S$13,688 (30 September 2025: S$6,279).

### 14. Borrowings

| | Group | | Company | |
|---|---|---|---|---|
| | 30 September 2026 (Unaudited) S$'000 | 31 March 2026 (Audited) S$'000 | 30 September 2026 (Unaudited) S$'000 | 31 March 2026 (Audited) S$'000 |
| **Current** | | | | |
| *Unsecured* | | | | |
| Term loan I | - | 262 | - | - |
| | - | 262 | - | - |

Term Loan I was arranged at a fixed rate and was repayable over 60 months. It was secured by a corporate guarantee provided by the Company. It was fully repaid during the six months ended 30 September 2026.

### 15. Related Party Transactions

There are no material related party transactions apart from those disclosed elsewhere in the financial statements.

### 16. Share Capital

| | Group and Company | | | |
|---|---|---|---|---|
| | 30 September 2026 (Unaudited) | 31 March 2026 (Audited) | 30 September 2026 (Unaudited) | 31 March 2026 (Audited) |
| | Number of ordinary shares | | S$ | S$ |
| **Issued and fully-paid:** | | | | |
| Balance at beginning of financial period/year | 134,543,843 | 132,691,176 | 14,988,167 | 14,571,317 |
| Purchase of treasury shares | - | (814,000) | - | (185,078) |
| Issue of ordinary shares | - | 1,852,667 | - | 416,850 |
| Transferred to vendor as acquisition consideration | - | 814,000 | - | 185,078 |
| Balance at end of financial period/year | 134,543,843 | 134,543,843 | 14,988,167 | 14,988,167 |

## F. Notes to the Condensed Interim Consolidated Financial Statements (cont'd)

### 16. Share Capital (cont'd)

The Company had no treasury shares as at 30 September 2026.

The Company had 814,000 treasury shares (representing 0.62% of the Company's total issued share capital (excluding treasury shares)) as at 30 September 2025.

There were no outstanding convertibles or subsidiary holdings as at 30 September 2025 or 30 September 2026.

There were no sales, transfers, cancellation and/or use of treasury shares or subsidiary holdings as at the end of the current financial period reported on.

### 17. Subsequent events

There are no known subsequent events which have led to adjustments to this set of interim financial statements.

**G. Other information required pursuant to Appendix 7C of the Catalist Rules**

**1. Whether the figures have been audited, or reviewed and in accordance with which auditing standard or practice.**

The condensed consolidated statement of financial position of Medinex Limited and its subsidiaries (collectively, the "**Group**") as at 30 September 2026 and the related condensed consolidated profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six-month period then ended and certain explanatory notes have not been audited or reviewed.

**2. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:**

**(a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and**

**(b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on**

**Review for the performance of the Group for the six months ended 30 September 2026 ("HY2027") as compared to the six months ended 30 September 2025 ("HY2026")**

**CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME**

Revenue

The Group recorded a decrease in revenue of approximately S$0.75 million, or 12.45% in HY2027 as compared to HY2026. This decline was mainly attributable to decreases in revenue of (a) approximately S$0.14 million from the medical support services segment; (b) approximately S$0.15 million from the pharmaceutical services segment, mainly due to the loss of a major customer of the Group's subsidiary, Nex; (c) approximately S$0.24 million from the medical services segment, primarily due to the Group's exit from this market following the disposal of its subsidiary, Express Medical Pte. Ltd. ("**EM**"), in FY2026; and (d) S$0.22 million from the business support services segment.

Other items of income

Other income, which comprised mainly fixed deposit interest, government grants, dividend income and gain on fair value of financial assets at FVTPL, decreased by approximately S$0.87 million, or 90.48%, in HY2027 as compared to HY2026.

This decrease was primarily attributable to a loss on fair value of financial assets at FVTPL of approximately S$0.11 million recognised under other expenses in HY2027, as compared to a gain on fair value of financial assets at FVTPL of approximately S$0.88 million recognised under other income in HY2026. This was partially offset by an increase in gains on disposal of financial assets at FVTPL of approximately S$0.02 million, while other income components recorded a decrease of approximately S$0.01 million.

The reversal of loss allowance on trade receivables amounted to approximately S$0.04 million in HY2027, as compared to approximately S$0.08 million in HY2026, due to a lower amount of recovery and settlement of previously impaired trade receivables during HY2027.

Items of expenses

Inventories and consumables used and changes in inventories decreased by approximately S$0.18 million in HY2027 as compared to HY2026, mainly due to lower demand for medical services and pharmaceutical products following the loss of a major customer of the Group's subsidiary, Nex.

**G. Other information required pursuant to Appendix 7C of the Catalist Rules (cont'd)**

**CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (cont'd)**

Items of expenses (cont'd)

Amortisation and depreciation expenses decreased by approximately S$0.09 million in HY2027 as compared to HY2026, mainly attributable to (a) a decrease in amortisation of intangible assets of approximately S$0.04 million, primarily due to the customer relationships intangible assets having been fully amortised in FY2026; and (b) a decrease in depreciation of ROU assets of approximately S$0.06 million, partially offset by (c) an increase in depreciation of plant and equipment of approximately S$0.01 million.

Employee benefits expense decreased by approximately S$0.24 million in HY2027. This cost efficiency was driven by strategic hiring of staff located overseas.

Loss allowance on trade receivables increased by approximately S$0.03 million, mainly due to the increase in long outstanding trade receivables.

Other expenses decreased by approximately S$0.10 million in HY2027 as compared to HY2026, mainly attributable to decreases in (a) freelancer expenses of S$0.04 million; (b) consultancy fees of S$0.03 million; (c) platform fees of S$0.01 million; (d) cost of services of S$0.04 million; (e) transport expenses of S$0.01 million; (f) subscription fees of S$0.02 million; and (g) bad debts written off of S$0.01 million. These decreases were partially offset by increases in (a) professional fees of S$0.01 million; and (b) loss on fair value of financial assets at FVTPL of approximately S$0.11 million.

Share of results of joint ventures, net of tax, increased by approximately S$0.05 million, driven by higher profits recorded by Healthcare Essentials Pte Ltd ("**HEPL**").

Profit before income tax

As a result of the abovementioned, profit before income tax decreased by approximately S$1.04 million or approximately 45.99%.

Income tax expense

Income tax expenses decreased by approximately S$0.06 million or approximately 34.36% due to a lower taxable profit attained during the financial period.

**CONSOLIDATED STATEMENT OF FINANCIAL POSITION**

**The comparative performance for the assets and liabilities are based on the Group's financial statements as at 30 September 2026 and 31 March 2026.**

Non-current assets

The Group's non-current assets as at 30 September 2026 comprise plant and equipment ("**PPE**"), right-of-use ("**ROU**") assets, intangible assets, investment in joint ventures and financial assets at FVTPL.

The Group's PPE decreased by approximately S$0.02 million mainly due to depreciation of approximately S$0.03 million and was partially offset by the addition of computers of approximately S$0.01 million.

The Group's ROU assets decreased by approximately S$0.14 million due to depreciation.

**G. Other information required pursuant to Appendix 7C of the Catalist Rules (cont'd)**

**CONSOLIDATED STATEMENT OF FINANCIAL POSITION (cont'd)**

Non-current assets (cont'd)

The Group's investment in joint venture increased by approximately S$0.07 million due to the profit from HEPL in HY2027 and net of dividend from HEPL.

Financial assets at FVTPL decreased by approximately S$0.12 million as a result of fair value loss in investment in quoted equity securities.

Current assets

Inventories decreased by approximately S$0.03 million mainly due to lower demand for medical services and pharmaceutical products following the loss of a major customer under the Group's subsidiary, Nex.

Trade and other receivables decreased by approximately S$0.61 million, mainly due to (a) a decrease in trade and other receivables by S$0.52 million; (b) a decrease in bank interest receivables and dividend receivables by S$0.08 million; and (c) a decrease in deposits receivables by S$0.01 million.

Contract assets decreased by approximately S$0.04 million, primarily due to the transfer of previously recognised contract assets to trade receivables upon the recognition of revenue earned in HY2027.

Prepayments decreased by approximately S$0.05 million, mainly due to the amortisation of supplier prepayments recognised as expenses during HY2027.

Fixed deposits decreased by S$2.00 million following the maturity and full withdrawal of the fixed deposit during HY2027.

Equity

The retained earnings decreased by S$0.02 million mainly due to the profit earned of approximately S$1.11 million during HY2027, offset by the interim dividend for FY2027 amounting to approximately S$1.13 million paid.

Liabilities

The Group's lease liabilities (non-current and current) decreased by approximately S$0.13 million due to lease repayments made during the financial period.

The Group's current bank borrowings decreased by approximately S$0.26 million, due to the full repayment of the bank loan during HY2027.

Other current liabilities

Trade and other payables decreased by approximately S$0.25 million, mainly attributable to (a) a net decrease in accruals and salaries of approximately S$0.15 million; and (b) a decrease in trade payables of approximately S$0.11 million, partially offset by an increase in other payables of approximately S$0.01 million.

Contract liabilities decreased by approximately S$0.26 million, mainly due to a decrease in advance payments received from customers and deferred income of approximately S$0.02 million and S$0.24 million, respectively.

Current income tax payable increased by approximately S$0.11 million, mainly due to higher taxable profits during HY2027.

**G. Other information required pursuant to Appendix 7C of the Catalist Rules (cont'd)**

**CONSOLIDATED STATEMENT OF CASH FLOWS**

The Group recorded net cash generated from operating activities of approximately S$1.53 million in HY2027, mainly attributable to operating cash flow before changes in working capital of approximately S$1.34 million, adjusted for net working capital inflow and income tax paid of approximately S$0.19 million. The net working capital inflow was mainly due to decreases in (a) inventories of approximately S$0.03 million; (b) trade and other receivables of approximately S$0.58 million; and (c) prepayments of approximately S$0.05 million, partially offset by (a) a net cash outflow of approximately S$0.22 million arising from movements in contract assets and contract liabilities; and (b) trade and other payables of approximately S$0.25 million.

Net cash generated from investing activities of approximately S$0.13 million in HY2027 was mainly attributable to (a) dividend income received from joint venture of approximately S$0.04 million; (b) dividend income received from financial assets at FVTPL amounting to an aggregate of approximately S$0.01 million; (c) interest received of approximately S$0.05 million; and (d) proceeds from disposal of financial assets at FVTPL amounting to approximately S$1.22 million. These were partially offset by the (a) investment in financial assets at FVTPL of approximately S$1.18 million; and (b) purchase of PPE of approximately S$0.01 million.

Net cash used in financing activities amounted to approximately S$1.54 million in HY2027, mainly due to (a) dividend payments to shareholders of the Company of approximately S$1.13 million; (b) repayment of the principal and interest portions of lease liabilities amounting to an aggregate of approximately S$0.15 million; and (c) repayment of bank borrowings and related interest amounting to an aggregate of approximately S$0.26 million.

As a result of the abovementioned, the Group recorded a net increase in cash and cash equivalents of approximately S$0.12 million in HY2027.

**3. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it** and **the actual results.**

Not applicable as no forecast or prospect statement has been disclosed previously.

**G. Other information required pursuant to Appendix 7C of the Catalist Rules (cont'd)**

**4. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.**

The business landscape continues to evolve rapidly, driven by advancements in artificial intelligence ("AI"), changing workforce dynamics and persistent pricing pressures that continue to shape customer expectations and purchasing behaviour. These developments are transforming the way organisations operate and procure professional and support services, presenting both challenges and opportunities across the sectors in which the Group operates.

While the Group's operating performance for the first half of FY2027 was marginally lower than the corresponding period last year, management believes this was largely attributable to the prevailing market conditions especially the pricing pressures mentioned above and the timing of project-based revenue recognition, rather than any deterioration in the fundamentals of the Group's business.

Looking ahead, the Group remains focused on strengthening its market position and expanding its regional footprint. To demonstrate its commitment to regional expansion, the Group has established a taskforce to work towards establishing a presence in Malaysia and developing relationships with local business partners through its accounting, tax and payroll capabilities.

The Group is also capitalising on opportunities arising from AI adoption, digital transformation and evolving customer needs. In addition, the Group is investing in sustainability capabilities to enhance its service offerings and support clients in addressing growing environmental, social and governance ("ESG") expectations and reporting requirements.

The Board believes that these strategic initiatives, together with the Group's sector expertise, established client relationships and commitment to innovation, will position the Group well to navigate the evolving business environment and deliver sustainable long-term value for shareholders.

**G. Other information required pursuant to Appendix 7C of the Catalist Rules (cont'd)**

**5. Dividend**

If a decision regarding dividend has been made: -

(a) Whether an interim (final) ordinary dividend has been declared (recommended); and

Yes.

| | |
|---|---|
| Name of Dividend | Interim |
| Dividend Type | Ordinary |
| Dividend Amount per Share (in S$ cents) | 0.84 cents per ordinary share (one tier tax) |
| Tax Rate | Tax exempt |

The distribution of the interim dividends represents approximately 102% of the Group's net profit after tax attributable to owners of the company for the financial period from 1 April 2026 to 30 September 2026.

(b) (i) Amount per share (cents)

Please refer to paragraph 5(a).

(ii) Previous corresponding period (cents)

| | |
|---|---|
| Name of Dividend | Interim |
| Dividend Type | Ordinary |
| Dividend Amount per Share (in S$ cents) | 0.84 cents per ordinary share (one tier tax) |
| Tax Rate | Tax exempt |

(c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated.)

Please refer to paragraph 5(a).

(d) The date the dividend is payable.

The dividend will be paid on 30 December 2026.

(e) The date on which Registrable Transfers received by the Company (up to 5.00pm) will be registered before entitlements to the dividend are determined.

Notice is hereby given that the Share Transfer Books and the Register of Members of the Company will be closed at 5.00 p.m. on 18 December 2026 for the purpose of determining shareholders' entitlements to the interim dividend.

Duly completed transfers of shares received by the Company's Share Registrar, Tricor Barbinder Share Registration Services (A division of Tricor Singapore Pte. Ltd.) at 9 Raffles Place, #26-01 Republic Plaza, Singapore 048619, up to 5.00 p.m. on 18 December 2026 will be registered to determine shareholders' entitlements to the interim dividend.

Shareholders (being depositors) whose securities accounts with The Central Depository (Pte) Limited are credited with shares as at 5.00 p.m. on 18 December 2026 will be entitled to the interim dividend.

**G. Other information required pursuant to Appendix 7C of the Catalist Rules (cont'd)**

**6. Interested Party Transactions ("IPTs")**

The Group has not obtained a general mandate from shareholders for IPTs.

The Group did not enter into any IPTs with a value of S$100,000 or more in HY2027.

**7. Use of IPO Proceeds**

The Company refers to the net cash proceeds amounting to S$5.28 million (excluding cash listing expenses of approximately S$1.22 million) raised from the IPO on the Catalist Board of SGX-ST on 7 December 2018.

As at the date of this announcement, the status on the use of the IPO net proceeds is as follows:

| | Amount allocated (S$'000) | Amount utilised (S$'000) | Balance (S$'000) |
|---|---|---|---|
| Expand our Group's business operations via acquisitions, joint ventures and/or strategic partnerships | 4,000.00 | 3,532.50[(1)] | 467.50 |
| Working Capital | 1,316.00 | 786.00[(2)] | 530.00 |
| Total | 5,316.00 | 4,318.50 | 997.50 |

Notes:

(1) Utilised for the following:-
(a) acquisition of Sen Med Holdings Pte. Ltd. - S$1,732,500;
(b) acquisition of ARK - S$600,000; and
(c) acquisition of SKI Consultancy Pte Ltd and MDX Advisory Pte. Ltd. – S$1,200,000.

(2) Utilised for the payment of listing expenses of S$36,000 and the provision of the convertible loan amount of S$750,000 to Singapore Paincare Holdings Limited.

The utilisation is in accordance with the intended use as stated in the Company's offer document dated 30 November 2018.

**8. Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1)**

The Company confirms that it has procured undertaking from all its directors and executive officers (in the format as set out in Appendix 7H) under Rule 720(1) of the SGX-ST Listing Manual Section B: Rules of Catalist (**"Catalist Rules"**).

**9. Negative Confirmation by the Board pursuant to Rule 705(5) of the Catalist Rules**

On behalf of the Board of Directors of the Company, we, the undersigned, hereby confirm to the best of our knowledge that nothing has come to the attention of the Board of Directors of the Company which may render the financial statements for the six-month period ended 30 September 2026 to be false or misleading in any material aspect.

**BY ORDER OF THE BOARD**

Jessie Low Mui Choo
Executive Director and Chief Executive Officer

Tan Lee Meng
Non-Executive Chairman

Singapore
12 November 2026